Brief: Impact Therapeutics Says Senaparib Submitted To European Commission For Final Marketing Authorization Decision
18/09/2026 16:37
BRIEF-Impact Therapeutics Says Senaparib Submitted To European Commission For Final Marketing Authorization Decision Sept 18 (Reuters) - IMPACT Therapeutics Inc 7630.HK:
SENAPARIB SUBMITTED TO EUROPEAN COMMISSION FOR FINAL MARKETING AUTHORIZATION DECISION
Further company coverage: 7630.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IMPACT Therapeutics
See all newsBrief: Impact Therapeutics Says Senaparib Submitted To European Commission For Final Marketing Authorization Decision
Brief: Impact Therapeutics Says CEO Purchases 100,000 Ordinary Shares At HK$14.6105 Per Share
Brief: IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, Others
Metis TechBio, IMPACT Therapeutics shine in Hong Kong debut
Brief: Impact Therapeutics Says Final Offer Price Under Global Offering Of Hk$20.10 Per H Share